Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase III, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)

被引：0
|
作者：
Blauvelt, A. [1 ]
Wollenberg, A. [2 ]
Pink, A. [3 ]
Peris, K. [4 ,5 ]
Armstrong, A. [6 ]
Spelman, L. [7 ,8 ]
Saeki, H. [9 ]
Lynde, C. [10 ,11 ]
Herranz, P. [12 ]
Barbarot, S. [13 ]
Simpson, E. [14 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany
[3] Guys & St Thomas Hosp, St Johns Inst Dermatol, London, England
[4] Catholic Univ, Dermatol, Rome, Italy
[5] IRCCS, Fdn Policlin Univ A Gemelli, Rome, Italy
[6] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA 90007 USA
[7] Verac Clin Res, Brisbane, Qld, Australia
[8] Prob Med Res, Woolloongabba, Qld, Australia
[9] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[10] Prob Med Res, Lynde Dermatol, Markham, ON, Canada
[11] Univ Toronto, Dept Med, Toronto, ON, Canada
[12] Hosp Univ La Paz, Dept Dermatol, Madrid, Spain
[13] Ctr Hosp Univ Nantes, Nantes, France
[14] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
447
引用
收藏
页码：E110 / E111
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
    Ebisawa, Motohiro
    Kataoka, Yoko
    Tanaka, Akio
    Nagao, Mizuho
    Laws, Elizabeth
    Mortensen, Eric
    Nawata, Hisakatsu
    Arima, Kazuhiko
    Watanabe, Daisuke
    Lu, Xin
    Maloney, Jennifer
    Dubost-Brama, Ariane
    Bansal, Ashish
    Yahata, Kenji
    ALLERGOLOGY INTERNATIONAL, 2024, 73 (04) : 532 - 542
  • [32] A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
    Papp, K. A.
    Reich, K.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Krueger, J. G.
    Russell, C. B.
    Milmont, C. E.
    Li, J.
    Klekotka, P. A.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (02) : 273 - 286
  • [33] The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis
    Simon, J. C.
    Barbarot, S.
    Gooderham, M.
    Simpson, E.
    Kurbasic, A.
    Olsen, C. K.
    Cork, M. J.
    Silverberg, J., I
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 56 - 56
  • [34] EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN CHINESE ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: RATIONALE AND DESIGN OF A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE III TRIAL
    Zhao, Yan
    Lu, Qianjin
    Gao, Xinghua
    Liu, Lingling
    Li, Wei
    Song, Zhiqiang
    Yao, Zhirong
    Yao, Xu
    Hao, Nan
    Zhang, Jianzhong
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 52 - 53
  • [35] The efficacy of whey associated with dodder seed extract on moderate-to-severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled clinical trial
    Mehrbani, Mehrzad
    Choopani, Rasool
    Fekri, Alireza
    Mehrabani, Mitra
    Mosaddegh, Mahmoud
    Mehrabani, Mehrnaz
    JOURNAL OF ETHNOPHARMACOLOGY, 2015, 172 : 325 - 332
  • [36] Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan
    Nakamura, Yu
    Kitamura, Shin
    Homma, Akira
    Shiosakai, Kazuhito
    Matsui, Daiju
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 913 - 925
  • [37] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [38] Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study
    Dogra, Sunil
    Krupashankar
    Budamakuntla, Leelavathy
    Srinivas, C. R.
    Khopkar, Uday
    Gupta, Sandesh
    Shetty, Narendra
    Pratap, Dasiga Venkata Subrahmanya
    Gopal, M. G.
    Rao, T. Narayana
    Garg, Vijay
    Sumathy, T. K.
    Saraswat, Abir
    Bhat, Ramesh
    Kura, Mahendra
    Pandey, Neeraj
    Shah, Radha
    Krishna, Kotla Sai
    Padmaja, Dalavai
    Manmohan, G.
    Ramakrishnan, M. S.
    Barve, Abhijit
    Montero, Enrique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (02) : 331 - 333
  • [39] Lebrikizumab treatment improves quality of life in patients with moderate-to-severe atopic dermatitis: results from two phase III randomized, double-blinded, placebo-controlled trials (ADvocate1 and ADvocate2)
    Lio, Peter
    Armstrong, April
    Gutermuth, Jan
    Nosbaum, Audrey
    Sofen, Howard
    Casillas, Marta
    Pierce, Evangeline
    Elmaraghy, Hany
    Chen, Sherry
    Thyssen, Jacob P.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E109 - E110
  • [40] Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Yamamoto, Chie
    Igawa, Ken
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 192 (04) : 597 - 610
12345